A randomised, double-blind phase 3 trial compared once-daily oral safiglipron, a small-molecule GLP-1 receptor agonist, with dapagliflozin in adults with type 2 diabetes. Safiglipron was non-inferior for HbA1c reduction at every dose tested and superior at 90 mg, with greater improvement in glycaemic control overall. Weight loss was similar and modest in both arms, and the safety profile was reported as acceptable.
Why it is interesting: A phase 3 comparison of an oral small-molecule GLP-1 agonist against a standard oral agent rather than placebo.